GlassScriptPhysician profile
Abdi Morovati
NPI 1417000563
$16,048.06
in general payments reported to CMS, 2019-2025
60 companies · $1,915 in 2025
The $1,915 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,791 · 2020: $1,749 · 2021: $3,674 · 2022: $4,260 · 2023: $2,335 · 2024: $324 · 2025: $1,915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,573.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,459.21 | 2021-2025 | |
| Upsher-Smith Laboratories LLC | $1,073.33 | 2019-2023 | |
| Amneal Pharmaceuticals LLC | $1,064.83 | 2019-2025 | Rytary, Crexont |
| Genzyme Corporation | $914.36 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $914.34 | 2019-2024 | |
| Neurocrine Biosciences, INC. | $748.87 | 2020-2023 | Ongentys, Ingrezza |
| Teva Pharmaceuticals USA, INC. | $735.18 | 2019-2023 | Austedo |
| Amgen INC. | $700.93 | 2019-2022 | |
| Sk Life Science, INC. | $682.91 | 2021-2025 | |
| Lilly USA, LLC | $663.46 | 2019-2025 | Amyvid, Reyvow, Emgality |
| Lundbeck LLC | $592.62 | 2020-2025 | Vyepti |
| Ucb, INC. | $491.22 | 2019-2023 | Briviact |
| Allergan, INC. | $455.66 | 2019-2021 | |
| Eisai INC. | $392.40 | 2019-2025 | |
| Pfizer INC. | $341.89 | 2023-2025 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdi Morovati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.